Every telehealth ad is judged by two referees: the platform that can reject it, and the regulator that can send a warning letter. They fail you for different reasons — and the claims that feel most persuasive are usually the ones that trip both. Here's how to write claims that convert and clear review.
Most telehealth founders treat "ad rejected" and "compliance risk" as the same problem. They're not. The platform (Meta, Google) rejects ads that break its health-advertising standards — before/after images, miracle or guaranteed outcomes, body-image pressure, targeting that implies it knows your health condition, or promoting drugs it won't allow. The regulator (FDA, FTC) doesn't care if your ad ran; it cares whether the claim was false or misleading once it did. A claim can sail through Meta review and still be exactly what earns a warning letter.
The claims that feel most persuasive — "as effective as the brand," "guaranteed results," "lose 20 lbs" — are usually the ones that trip both referees at once. The job isn't to write timid copy. It's to write claims that are specific, supportable, and honest about limits — which, conveniently, also convert better with a skeptical patient.
These are the patterns platforms reject and regulators cite. Since launching its crackdown in September 2025, the FDA has sent thousands of letters to pharma and telehealth firms over misleading drug ads — more than in the entire preceding decade — including 30 to telehealth companies on March 3, 2026. The violations rhyme. Mark any your current ads lean on.
Implying a compounded drug is equivalent to the FDA-approved brand — "same active ingredient," "same as Ozempic." This is the single most-cited violation in the FDA's GLP-1 letters. Compounded products aren't FDA-reviewed for safety, efficacy, or quality, and saying otherwise is the line they're enforcing.
Weight-loss before-and-after photos are prohibited under Meta's health-ad standards, full stop — even real, unretouched ones. So are zoomed-in body shots that imply a "problem" to fix.
"Lose 20 lbs in a month," "guaranteed results," "melts fat." Platforms reject exaggerated or guaranteed-outcome claims; regulators treat unsubstantiated efficacy claims as misleading. Specific, typical, sourced beats dramatic.
Copy that asserts or implies it knows the viewer's condition — "Struggling with your weight?", "Your diabetes…" Meta's personal-attributes rule bans implying knowledge of a person's health. Speak to the situation, not the person's body.
Branded prescription claims that tout benefit without the corresponding risk information. For approved drugs, benefit and risk have to travel together; an ad that's all upside is both a platform and a regulatory problem.
Promoting prescription drugs or an online pharmacy without the platform's required authorization and verification, or obscuring who actually compounds and is responsible. Hiding the source is a documented FDA citation, not a technicality.
You rarely have to drop the message — you have to make it specific and honest. These rewrites keep the persuasion and lose the trigger. (Illustrative patterns, not approved copy: your medical and legal reviewers have the final say, and platform policies change.)
Since launching its crackdown in September 2025, the FDA has sent thousands of warning letters to pharma and telehealth firms over misleading drug ads — more than in the entire preceding decade — including 30 to telehealth companies on March 3, 2026. The repeat citations are consistent: implying a compounded drug is the same as an FDA-approved one, and obscuring who actually compounds it by branding the product with the telehealth firm's own name. Platform rejection costs you a campaign; a warning letter or a consent decree can cost you the ability to advertise at all. Write the claim that survives both reads from the start. (Operator judgment, not legal or regulatory advice — your medical, regulatory, and legal reviewers make the call, and platform standards change often.)
Read your ad — headline, body, image, landing page — against each question. A "yes" to any of the first five is a likely rejection or citation. The goal isn't a timid ad; it's a specific, supportable one.
Does any line imply a compounded product is the same as, or as good as, the FDA-approved brand?
Is it accurate about what the product actually is?
Any guaranteed, miracle, or specific-number weight-loss promise?
Can every efficacy claim be supported if a regulator asked?
Any before/after, or body shots that imply a "problem" to fix?
Does the visual show the care, the clinician, or the process instead?
Does the copy assert or imply it knows the viewer's condition ("your weight," "your diabetes")?
Can it speak to the situation instead of the person's body?
For a branded drug claim, does benefit travel with the risk information?
Is it clear who prescribes, compounds, and is responsible?
Has a clinician reviewed the claims, and is the platform authorization/verification in place?
Who gives final approval before this goes live?
Bring your ads, landing pages, and claims. We'll flag what's likely to get rejected or cited, and rewrite it to convert and clear review — the claims judgment a generic agency can't give you. That's the Growth and Scaling engagement. (Operator judgment, not legal or regulatory advice — your medical, regulatory, and legal reviewers make the final call.)
Grounded in the U.S. FDA's 2025–2026 warning letters to telehealth and compounding sellers over GLP-1 marketing, and Meta's published health, wellness, and drugs & pharmaceuticals advertising standards. Platform policies and enforcement priorities change frequently; confirm the current standards and consult qualified medical, regulatory, and legal advisors before publishing.